Wall Street Experts
ver. ZuMIgo(08/25)
Kiniksa Pharmaceuticals, Ltd.
Rachunek Zysków i Strat
Przychody TTM (mln): 384
EBIT TTM (mln): -27
index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
Rok finansowy |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Przychód (mln) |
0 |
0 |
0 |
0 |
0 |
39 |
220 |
270 |
423 |
Przychód Δ r/r |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
inf% |
471.2% |
22.7% |
56.6% |
Marża brutto |
0.0% |
0.0% |
0.0% |
-inf% |
-inf% |
76.4% |
78.7% |
66.3% |
100.0% |
EBIT (mln) |
-24 |
-65 |
-108 |
-170 |
-157 |
-157 |
7 |
-25 |
-46 |
EBIT Δ r/r |
0.0% |
172.5% |
65.4% |
57.1% |
-7.4% |
-0.5% |
-104.7% |
-441.8% |
81.0% |
EBIT (%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
-406.4% |
3.3% |
-9.3% |
-10.8% |
Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
EBITDA (mln) |
-24 |
-65 |
-108 |
-170 |
-157 |
-157 |
10 |
-23 |
-46 |
EBITDA(%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
-406.4% |
4.4% |
-8.5% |
-10.8% |
Podatek (mln) |
0 |
0 |
-0 |
-2 |
5 |
1 |
-172 |
-31 |
7 |
Zysk Netto (mln) |
-24 |
-65 |
-103 |
-162 |
-161 |
-158 |
183 |
14 |
-43 |
Zysk netto Δ r/r |
0.0% |
170.6% |
59.1% |
56.8% |
-0.3% |
-2.1% |
-216.1% |
-92.3% |
-406.7% |
Zysk netto (%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
-409.7% |
83.3% |
5.2% |
-10.2% |
EPS |
-0.74 |
-2.0 |
-3.49 |
-2.99 |
-2.61 |
-2.3 |
2.64 |
0.2 |
-0.6 |
EPS (rozwodnione) |
-0.74 |
-2.0 |
-3.49 |
-2.99 |
-2.61 |
-2.3 |
2.6 |
0.2 |
-0.6 |
Ilośc akcji (mln) |
32 |
32 |
30 |
54 |
62 |
69 |
69 |
70 |
71 |
Ważona ilośc akcji (mln) |
32 |
32 |
30 |
54 |
62 |
69 |
70 |
72 |
71 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |